COMMUNIQUÉS West-GlobeNewswire

Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer
19/05/2026
BASEL, Switzerland, May 19, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage biotechnology company pioneering precision biologics to reprogram the immune system for the treatment of autoimmune and inflammatory diseases, [...]
HEPHAISTOS-Pharma appoints Stephan Braun as Chief Medical Officer to lead clinical development strategy
19/05/2026
HEPHAISTOS-Pharma appoints Stephan Braun as Chief Medical Officer to lead clinical development strategy Former ImCheck Therapeutics clinical leader joins HEPHAISTOS-Pharma as the company prepares to advance its lead [...]
GenoSafe advances CLIA pathway for transatlantic ATMP development
19/05/2026
GenoSafe advances CLIA pathway for transatlantic ATMP development CLIA registration enables GenoSafe to support testing of samples from U.S.-based patients enrolled in clinical trials. This milestone strengthens [...]
FEATOL Introduces Ergonomic Wrist Support for Modern Repetitive Strain Challenges
19/05/2026
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- FEATOL has introduced the FEATOL 2 Pack Carpal Tunnel Wrist Brace, a wrist support solution for daily stabilization, pain relief, and recovery support. The brace is made for [...]
Transactions in connection with share buy-back program
19/05/2026
Company announcement no. 17 - 26 19 May 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial
19/05/2026
-- STARLYS trial to evaluate the potential of MST-0312, a targeted lymphotoxin-beta (LTBR) agonist bispecific antibody, as a novel therapeutic strategy for the treatment of solid tumors. -- Study to evaluate tertiary [...]
AdrenoMed Highlights Need for Personalized Therapies in Septic Shock Amid New Sepsis Guidelines and U.S. Policy Initiative
19/05/2026
Hennigsdorf / Berlin (Germany), May 19, 2026 (GLOBE NEWSWIRE) -- Press Release AdrenoMed Highlights Need for Personalized Therapies in Septic Shock Amid New Sepsis Guidelines and U.S. Policy Initiative 2026 Surviving [...]
Khondrion Announces First Patient Dosed in Phase II Study Targeting Debilitating Post-COVID Fatigue
19/05/2026
SON4PEM trial advances development of sonlicromanol, aiming to address chronic fatigue in Post-COVID patients with post-exertional malaise NIJMEGEN, The Netherlands, May 19, 2026 (GLOBE NEWSWIRE) -- Khondrion today [...]
ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026
19/05/2026
EINDHOVEN, The Netherlands, May 19, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence [...]
Unaudited Preliminary Results for the Year Ended December 31, 2025
19/05/2026
LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery [...]
Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer
19/05/2026
New giredestrant data from the lidERA study on its potential as a new standard of care for adjuvant ER-positive breast cancer across all menopausal stages Primary results from the persevERA study on the numerical [...]
SERB Pharmaceuticals to acquire European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma for €115 million
19/05/2026
BRUSSELS, May 19, 2026 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals (“SERB”) and Hansa Biopharma AB (“Hansa”) (Nasdaq Stockholm: HNSA) today announced that they have entered into an agreement under which SERB will acquire [...]
Fangzhou Ranked among 2025 Guangzhou AI Innovation “Most Promising Enterprises” for AI‑Powered Chronic Disease Services
19/05/2026
GUANGZHOU, China, May 19, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, was invited to attend the 2026 Guangzhou [...]
Rapid Micro Biosystems Announces Pricing of Up to Approximately $32 Million Underwritten Offering
19/05/2026
Bain Capital Life Sciences and Armistice Capital are investing approximately $9.8 million, with the potential of up to approximately $32 million in the event the warrants offered in this offering are exercised, to [...]
Rapid Nutrition Advances Finalization of Australian Flagship Initiative
19/05/2026
LONDON, May 19, 2026 (GLOBE NEWSWIRE) -- Rapid Nutrition PLC (Euronext Growth: ALRPD ), a global HealthTech company focused on evidence-based nutrition brands, is pleased to provide an update regarding its Australian [...]
Pennant Group to Participate in the 2026 RBC Global Healthcare Conference
19/05/2026
EAGLE, Idaho, May 18, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, announced today that it will [...]
Precision Optics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
18/05/2026
LITTLETON, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/ [...]
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18/05/2026
RESEARCH TRIANGLE PARK, N.C., May 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on May 11, 2026, [...]
Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
18/05/2026
CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in [...]

Pages